

# Company Fact Sheet

July 2025 (Data as of 30 June 2025)

**HBM** Healthcare  
Investments

Unique investments in private and listed life sciences companies

## Profile

Swiss investment company with \$2.0 billion assets  
holding a global portfolio of emerging life sciences companies

<b>Unique</b> Swiss-based, permanent capital, healthcare-dedicated investment vehicle to invest in both private and public companies	<b>Investments</b> Focusing on growth companies in the biotech, medtech, diagnostic and health IT sectors	<b>Portfolio companies</b> Achieved proof of concept and/or major clinical and regulatory milestones prior to investment	<b>Expertise</b> Dedicated investment teams for private equity and public equity with a global industry network and external business advisors
<b>HBM strategy</b> Validated by over 70 trade sales or IPOs over the last decade	<b>Portfolio mix</b> Lower volatility of NAV through private equity investments and opportunistic hedging	<b>Distribution</b> Attractive distribution policy with 3-5% yield target p.a. (based on the share price)	<b>Established in 2001</b> And SIX Swiss Exchange-listed since 2008 with approx. 3'800 shareholders

## Key Figures (in CHF, data as of 30 June 2025)

Total Assets	1'625 million
Net Assets (NAV)*	1'451 million
Market Capitalisation	1'153 million

NAV per share	216.35
Share Price	171.00
Premium (+) / Discount (-)	-20.9%

LTM daily trading volume ~5'900 shares ~ 1.1 million

Number of issued shares	6.74 million
Number of shareholders	~ 3'800

## Performance

Return	MTD	CYTD	3y p.a.	5y p.a.	10y p.a.
NAV	-2.8%	-10.9%	-4.9%	2.3%	9.9%
Share Price	0.1%	-2.8%	-10.4%	-3.8%	9.3%

Return by Year	2025	2024	2023	2022	2021
NAV	-10.9%	15.0%	-8.3%	-21.7%	19.0%
Share Price	-2.8%	0.5%	-5.4%	-37.8%	15.2%


Total return, incl. cash distributions

Distribution	2025	2024	2023	2022	2021
in CHF	7.50*	7.50	7.50	9.70	12.50**
Yield in %	4.1%	3.9%	3.5%	3.5%	3.8%

\* The net assets take into account the dividend of CHF 4.90 and the par value repayment of CHF 2.60, which will be distributed early July 2025.

\* Approved by AGM on 23 June 2025 - ex & payment date: 2.7. & 4.7.2025; \*\* includes special distribution of CHF 3.00 in 2021 to mark the 20th anniversary.

Indexed performance since launch in CHF (12.7.2001 = 100), distributions reinvested, Source: HBM & Bloomberg



## Investment Approach

- Fundamental long with private and public healthcare investments
- Focus on companies with innovative platforms and drug candidates
- Bottom-up selection of investments with solid long-term growth potential
- HBM takes an active role and assumes entrepreneurial responsibility together with the management team

## Reasons to Invest


- Access to a diversified portfolio of private and listed healthcare companies with value increasing potential
- Global orientation with focus on the US, but increasing allocation in emerging markets such as China and India
- Closed-end structure allows optimum exploitation of the value-increasing potential of healthcare companies
- Lower correlation to public market portfolios thanks to the substantial private capital allocation

# Portfolio Summary


## June 2025

**HBM** Healthcare Investments


By Geography (in % of total assets)




By Currency (in % of total assets)



By Therapeutic Area (in % of investments)



By Development Stage (in % of investments)




Data as of 30 June 2025


Investments: CHF 1'464 million;  
Development stage: Lead program by stage

## Asset Allocation


in CHF million



## Diversified Portfolio



## Asset Allocation in % total assets



*Dren Bio's clinical-stage program DR-0201 was acquired by Sanofi in the previous financial year, with the transaction being completed during the reporting period. HBM Healthcare continues to hold a stake in Dren Bio.*

Data as of 30 June 2025 (top 15 public and top 15 private), in % of total assets of CHF 1'625 million, Top 10 overall: 42.5%

# Portfolio Summary

## June 2025

**HBM** Healthcare Investments

### Largest Investments

Company	Core Business	Company Stage	Ticker	Market Capitalisation (CHF m)	Ownership (%)	Book Value (CHF m)	% of Total Assets
 <b>Swixx BioPharma</b> <small>Modern Medicines for All</small>	Full representation of biopharma companies in CEE, Eurasia, Latam and MENA	Profitable	Private	916*	25.1	214.7	13.2
 <b>CATHAY</b> <small>INDUSTRIAL BIOTECH</small>	Synthetic biology (long chain diacids, carbohydrates, special enzymes, green nylon)	Profitable	688065 CH (ex private)	3'760	4.9	185.7 <sup>1)</sup>	11.4
 <b>H3 HARMONY BIOSCIENCES, LLC</b>	Drug for the treatment of narcolepsy (with and without cataplexy)	Profitable	HRMY (ex private)	1'439	3.7	53.8	3.3
 <b>NEURELIS</b>	Nasal spray for the treatment of epileptic seizures	Market	Private	434	10.3	44.6	2.7
 <b>argenx</b>	Drugs for the treatment of severe autoimmune diseases (MG, ITP, PV & PF, CIPD)	Market	ARGX	27'449	0.2	43.8	2.7
 <b>Merus</b>	Bispecific antibody-based therapeutics for oncology	Phase III	MRUS	3'113	1.3	41.7	2.6
 <b>Sai</b>	Contract research, development, and manufacturing organization (CRO/CDMO)	Market	SAILIFE (ex private)	1'488	2.0	32.6	1.8
 <b>ARRIVENT</b>	Developing pharmaceutical products to cure presently untreatable cancer	Phase III	AVBP (ex private)	591	4.8	28.6	1.8
 <b>UpstreamBIO</b>	Monoclonal antibody targeting TSLP receptor in allergic and inflammatory diseases	Phase II	UBP (ex private)	468	5.1	23.6	1.5
 <b>健客</b> 买正品药上健客 <small>jianke.com</small>	China's leading B2C SmartCare service platform (online pharmacy, chronic disease management service center)	Market	6086.HK (ex private)	488	4.6	22.2	1.4
 <b>MINERALYS</b>	Developing therapies for the treatment of hypertension	Phase III	MLYS (ex private)	699	2.9	20.3	1.3
 <b>NKT</b>	Developing small molecule oncology medicines (eg HIF2a inhibition)	Phase I/II	Private	377*	5.3	20.3	1.2

1) Deferred tax on capital gain and VAT not included – separately accrued in the books of the company

\* Implied company valuation (for private companies)

Data as of 30 June 2025

# Company Fact Sheet

## July 2025

Unique investments in private and listed life science companies

### Information for Investors

Legal status	Closed-ended, listed investment company under Swiss law. Investments held through fully owned subsidiary in the Cayman Islands.
Listing	SIX Swiss Stock Exchange, Zurich
Ticker	HBMN
ISIN Number	CH0012627250
Trading liquidity	Daily, average daily trading volume of ~5'900 shares ~ CHF 1.1 million
Reporting currency	Swiss Franc (CHF)
Reporting frequency / NAV calculation	Quarterly financial reporting; Monthly fact sheet; Bi-monthly NAV publication (mid- and end of month), Ad-hoc media releases for potentially price sensitive information
Financial year end	31 March
Investment advisor	HBM Partners AG, Zug (Switzerland)
Prime Broker / Custodian	Morgan Stanley & Co International plc., London (UK); Bank of America Merrill Lynch, San Francisco (US); Standard Chartered Bank, Mumbai (IN); Citic Securities & Citic Bank, Shanghai (CN)
Auditor	Ernst & Young Ltd., Zurich
Inception Date	12 July 2001
Management fee	0.75% on net assets plus 0.75% on market capitalization, calculated and paid quarterly at the beginning of a quarter.
Performance fee	15% of increase of the net asset value above the high water mark, calculated and paid annually based on the audited year-end net asset value, provided that value increase is more than 5 %.
High water mark	NAV of CHF 283.07
Contact information	HBM Healthcare Investments AG, Bundesplatz 1, 6300 Zug, Switzerland Email: <a href="mailto:investor.relations@hbmhealthcare.com">investor.relations@hbmhealthcare.com</a>   <a href="http://www.hbmhealthcare.com">www.hbmhealthcare.com</a>

### Disclaimer

Marketing Material - for information purposes only

This document constitutes marketing material and is intended to be for information purposes only and should not be construed as an offer or recommendation for transactions. The information does not take into account any personal circumstances and does not qualify as general or personal investment recommendation or advice.

No representation is made or assurance is given that statements, opinions and views made herein are correct, or that the underlying information is accurate. No responsibility or liability can be accepted for errors of fact, opinion or omissions.

Statements regarding the past performance may not be understood as indication for the current or future performance. The value of investments and the income therefrom may fluctuate. A good past performance may possibly not be repeated in the future. It is possible that the investor will not be paid back the full amount invested. Performance data does not take into account any commissions and costs charged when units of the Fund are issued and redeemed. An investment entails risks, which are fully described in the individual offering documents.

Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions. The data provider and HBM shall have no liability in connection with third party data. 10/2024